For US residents only.

Understanding Treatment


The first and only FDA-approved treatment options for your BRAF V600E metastatic NSCLC

For patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, there is an option to take the first US Food and Drug Administration (FDA)-approved targeted therapy, TAFINLAR® (dabrafenib) capsules + MEKINIST® (trametinib) tablets.

How may TAFINLAR and MEKINIST be used to treat NSCLC?

TAFINLAR, in combination with MEKINIST, is prescription medication used to treat a type of lung cancer called NSCLC that has spread to other parts of the body (metastatic NSCLC), and that has a certain type of abnormal “BRAF V600E” gene.

Your health care provider will perform a test to make sure that TAFINLAR, in combination with MEKINIST, is right for you.

It is not known if TAFINLAR with MEKINIST is safe and effective in children.

Before starting treatment

It is important to keep an open dialogue with your health care provider. Tell your health care provider about all the medications you take and if you:

  • Have had bleeding problems or blood clots
  • Have stomach problems
  • Have inflammation of the colon
  • Have heart problems
  • Have eye problems
  • Have lung or breathing problems
  • Have high blood pressure (hypertension)
  • Have liver or kidney problems
  • Have diabetes
  • Plan to have surgery, dental, or other medical procedures
  • Have a deficiency of the glucose-6-phosphate dehydrogenase (G6PD) enzyme
  • Are pregnant or plan to become pregnant. TAFINLAR can harm your unborn baby
  • Are breastfeeding or plan to breastfeed. It is not known if TAFINLAR passes into your breast milk